CADL
Income statement / Annual
Last year (2023), Candel Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Candel Therapeutics, Inc.'s net income was -$37.94 M.
See Candel Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$125,000.00
|
$125,000.00
|
$125,000.00
|
$125,000.00
|
| Cost of Revenue |
$23.98 M |
$987,000.00 |
$232,000.00 |
$0.00 |
$6.61 M |
| Gross Profit |
-$23.98 M |
-$862,000.00 |
-$107,000.00 |
$125,000.00 |
-$6.48 M |
| Gross Profit Ratio |
0 |
-6.9 |
-0.86 |
1 |
-51.86 |
| Research and Development
Expenses |
$24.51 M
|
$20.79 M
|
$15.18 M
|
$8.75 M
|
$6.61 M
|
| General & Administrative
Expenses |
$13.72 M
|
$14.06 M
|
$10.67 M
|
$5.18 M
|
$2.56 M
|
| Selling & Marketing
Expenses |
$687,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$14.41 M
|
$14.06 M
|
$10.67 M
|
$5.18 M
|
$2.56 M
|
| Other Expenses |
-$24.51 M |
-$48,000.00 |
-$1.08 M |
-$624,000.00 |
-$571,000.00 |
| Operating Expenses |
$14.41 M |
$34.80 M |
$24.78 M |
$13.31 M |
$8.59 M |
| Cost And Expenses |
$38.39 M |
$34.80 M |
$24.78 M |
$13.31 M |
$8.59 M |
| Interest Income |
$0.00 |
$490,000.00 |
$53,000.00 |
$111,000.00 |
$1.07 M |
| Interest Expense |
$514,000.00 |
$490,000.00 |
$53,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$960,000.00
|
$987,000.00
|
$232,000.00
|
$91,000.00
|
$43,000.00
|
| EBITDA |
-$37.43 M
|
-$17.32 M
|
-$25.49 M
|
-$13.72 M
|
-$8.20 M
|
| EBITDA Ratio |
0 |
-408.35 |
-195.34 |
-67.92 |
-60.63 |
| Operating Income Ratio
|
0
|
-277.78
|
-205.81
|
-110.48
|
-72.3
|
| Total Other
Income/Expenses Net |
$452,000.00
|
$15.93 M
|
-$10.40 M
|
-$3.87 M
|
$797,000.00
|
| Income Before Tax |
-$37.94 M |
-$18.79 M |
-$36.12 M |
-$17.68 M |
-$8.24 M |
| Income Before Tax Ratio
|
0
|
-150.35
|
-288.99
|
-141.44
|
-65.92
|
| Income Tax Expense |
$0.00 |
-$15.93 M |
$53,000.00 |
$4.49 M |
-$226,000.00 |
| Net Income |
-$37.94 M |
-$2.87 M |
-$36.18 M |
-$22.17 M |
-$8.01 M |
| Net Income Ratio |
0 |
-22.93 |
-289.42 |
-177.39 |
-64.11 |
| EPS |
-1.31 |
-0.0994 |
-1.26 |
-0.76 |
-0.27 |
| EPS Diluted |
-1.31 |
-0.0994 |
-1.26 |
-0.76 |
-0.27 |
| Weighted Average Shares
Out |
$28.94 M
|
$28.82 M
|
$28.69 M
|
$29.15 M
|
$29.15 M
|
| Weighted Average Shares
Out Diluted |
$28.94 M
|
$28.82 M
|
$28.69 M
|
$29.15 M
|
$29.15 M
|
| Link |
|
|
|
|
|
